{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T03:45:04Z","timestamp":1766807104608,"version":"build-2065373602"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s10620-021-07134-8","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T08:02:45Z","timestamp":1625040165000},"page":"3395-3401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Risk Factors for Hepatic Hydrothorax in Cirrhosis Patients with Ascites \u2013 A Clinical Cohort Study"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7319-975X","authenticated-orcid":false,"given":"Thomas","family":"Deleuran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugh","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"Vilstrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Jepsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"7134_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-2007-1007200","volume":"17","author":"RM Strauss","year":"1997","unstructured":"Strauss RM, Boyer TD. Hepatic hydrothorax. Semin Liver Dis 1997;17:227\u2013232.","journal-title":"Semin Liver Dis"},{"key":"7134_CR2","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1001\/archinte.1991.00400120029005","volume":"151","author":"W Alberts","year":"1991","unstructured":"Alberts W, Salem AJ, Solomon DA et al. Hepatic hydrothorax: Cause and management. Arch Intern Med 1991;151:2383\u20132388.","journal-title":"Arch Intern Med"},{"key":"7134_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/00063198-200307000-00003","volume":"9","author":"GT Kinasewitz","year":"2003","unstructured":"Kinasewitz GT, Keddissi JI. Hepatic hydrothorax. Curr Opin Pulm Med 2003;9:261\u2013265.","journal-title":"Curr Opin Pulm Med"},{"key":"7134_CR4","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.4254\/wjh.v9.i31.1197","volume":"9","author":"DV Garbuzenko","year":"2017","unstructured":"Garbuzenko DV, Arefyev NO. Hepatic hydrothorax: An update and review of the literature. World J Hepatol 2017;9:1197\u20131204.","journal-title":"World J Hepatol"},{"key":"7134_CR5","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1097\/00003072-200110000-00027","volume":"26","author":"A Rajnish","year":"2001","unstructured":"Rajnish A, Sudhakar P. Diagnosis of hepatic hydrothorax by Tc-99m sulfur colloid peritoneal scintigraphy. Clin Nucl Med 2001;26:888.","journal-title":"Clin Nucl Med"},{"key":"7134_CR6","first-page":"566","volume":"26","author":"A Abbasi","year":"2016","unstructured":"Abbasi A, Bhutto AR, Alam MT et al. Frequency of hepatic hydrothorax and its association with Child Pugh Class in liver cirrhosis patients. J Coll Physicians Surg Pak 2016;26:566\u2013569.","journal-title":"J Coll Physicians Surg Pak"},{"key":"7134_CR7","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.1016\/S0168-8278(17)30541-X","volume":"66","author":"D Matei","year":"2017","unstructured":"Matei D, Pasca S, David A et al. Hepatic hydrothorax in patients with cirrhosis and ascites \u2013 2013; its prevalence and association with other cirrhosis complications [Abstract]. J Hepatol 2017;66:S135.","journal-title":"J Hepatol"},{"key":"7134_CR8","doi-asserted-by":"crossref","unstructured":"Sobotka LA, Spitzer C, Hinton A, et al. Management of hepatic hydrothorax and effect on length of stay, mortality, cost and 30-day hospital readmission. J Gastroenterol Hepatol 2019","DOI":"10.1111\/jgh.14842"},{"key":"7134_CR9","doi-asserted-by":"crossref","unstructured":"Jindal A, Mukund A, Kumar G, et al. Efficacy and safety of Transjugular intrahepatic portosystemic shunt in difficult-to-manage hydrothorax in cirrhosis. Liver International 2019","DOI":"10.1111\/liv.14200"},{"key":"7134_CR10","first-page":"6","volume":"70","author":"JY Wilputte","year":"2007","unstructured":"Wilputte JY, Goffette P, Zech F et al. The outcome after transjugular intrahepatic portosystemic shunt (TIPS) for hepatic hydrothorax is closely related to liver dysfunction: a long-term study in 28 patients. Acta Gastroenterol Belg 2007;70:6\u201310.","journal-title":"Acta Gastroenterol Belg"},{"key":"7134_CR11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/ajg.2009.634","volume":"105","author":"R Dhanasekaran","year":"2010","unstructured":"Dhanasekaran R, West JK, Gonzales PC et al. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis. Am J Gastroenterol 2010;105:635\u2013641.","journal-title":"Am J Gastroenterol"},{"key":"7134_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/MD.0000000000000025","volume":"93","author":"R Badillo","year":"2014","unstructured":"Badillo R, Rockey DC. Hepatic hydrothorax: clinical features, management and outcomes in 77 patients and review of the literature. Medicine 2014;93:135\u2013142.","journal-title":"Medicine"},{"key":"7134_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4103\/sjg.SJG_336_17","volume":"24","author":"TH Hung","year":"2018","unstructured":"Hung TH, Tseng CW, Tsai CC et al. The long-term outcomes of cirrhotic patients with pleural effusion. Saudi J Gastroenterol 2018;24:46\u201351.","journal-title":"Saudi J Gastroenterol"},{"key":"7134_CR14","doi-asserted-by":"publisher","unstructured":"O\u2019Leary JG, Rajender Reddy K, Tandon P, et al. Increased risk of ACLF and inpatient mortality in hospitalized patients with cirrhosis and hepatic hydrothorax. Dig Dis Sci 2020. https:\/\/doi.org\/10.1007\/s10620-020-06677-6","DOI":"10.1007\/s10620-020-06677-6"},{"key":"7134_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/gutjnl-2011-300157","volume":"61","author":"F Wong","year":"2012","unstructured":"Wong F, Watson H, Gerbes A et al. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut 2012;61:108\u2013116.","journal-title":"Gut"},{"key":"7134_CR16","doi-asserted-by":"crossref","unstructured":"Greenland S, Mansournia MA and Altman DG. Sparse data bias: a problem hiding in plain sight. BMJ 2016; 352: i1981.","DOI":"10.1136\/bmj.i1981"},{"key":"7134_CR17","first-page":"496","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. JAMA 1999;94:496\u2013509.","journal-title":"JAMA"},{"key":"7134_CR18","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1002\/sim.5762","volume":"32","author":"D Kuk","year":"2013","unstructured":"Kuk D, Varadhan R. Model selection in competing risks regression. Stat Med 2013;32:3077\u20133088.","journal-title":"Stat Med"},{"key":"7134_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-3-030-16399-0","volume-title":"Clinical Prediction Models","author":"EW Steyerberg","year":"2019","unstructured":"Steyerberg EW. Clinical Prediction Models, 2nd edn. Leiden, The Netherlands: Springer; 2019; 207\u2013224.","edition":"2"},{"key":"7134_CR20","doi-asserted-by":"crossref","unstructured":"Altman DG, Vergouwe Y, Royston P, et al. Prognosis and prognostic research: validating a prognostic model. BMJ 2009; 338: b605.","DOI":"10.1136\/bmj.b605"},{"key":"7134_CR21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/biostatistics\/kxt059","volume":"15","author":"M Wolbers","year":"2014","unstructured":"Wolbers M, Blanche P, Koller MT et al. Concordance for prognostic models with competing risks. Biostatistics 2014;15:526\u2013539.","journal-title":"Biostatistics"},{"key":"7134_CR22","doi-asserted-by":"crossref","unstructured":"Moons KGM, Kengne AP, Woodward M, et al. Risk prediction models: I. Development, internal validation and assessing the incremental value of a new (bio)marker. Heart 2012; 98: 683.","DOI":"10.1136\/heartjnl-2011-301246"},{"key":"7134_CR23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/apt.15882","volume":"52","author":"P Jepsen","year":"2020","unstructured":"Jepsen P, Watson H, Macdonald S et al. MELD remains the best predictor of mortality in outpatients with cirrhosis and severe ascites. Aliment Pharmacol Ther 2020;52:492\u2013499.","journal-title":"Aliment Pharmacol Ther"},{"key":"7134_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression Modeling Strategies","author":"FE Harrell","year":"2015","unstructured":"Harrell FE. Regression Modeling Strategies, 2nd edn. New York: Springer; 2015; 103\u2013142.","edition":"2"},{"key":"7134_CR25","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/hep.510250611","volume":"25","author":"FD Gordon","year":"1997","unstructured":"Gordon FD, Anastopoulos HT, Crenshaw W et al. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology 1997;25:1366\u20131369.","journal-title":"Hepatology"},{"key":"7134_CR26","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/00042737-200105000-00011","volume":"13","author":"V Siegerstetter","year":"2001","unstructured":"Siegerstetter V, Deibert P, Ochs A et al. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol 2001;13:529\u2013534.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"7134_CR27","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","volume":"393","author":"C Villanueva","year":"2019","unstructured":"Villanueva C, Albillos A, Genesc\u00e0 J et al. \u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2019;393:1597\u20131608.","journal-title":"Lancet"},{"key":"7134_CR28","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.23775","volume":"52","author":"T Serste","year":"2010","unstructured":"Serste T, Melot C, Francoz C et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010;52:1017\u20131022.","journal-title":"Hepatology"},{"key":"7134_CR29","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jhep.2016.11.001","volume":"66","author":"T Reiberger","year":"2017","unstructured":"Reiberger T, Mandorfer M. Beta adrenergic blockade and decompensated cirrhosis. J Hepatol 2017;66:849\u2013859.","journal-title":"J Hepatol"},{"key":"7134_CR30","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1002\/hep.28352","volume":"63","author":"L Bossen","year":"2016","unstructured":"Bossen L, Krag A, Vilstrup H et al. Nonselective beta-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients. Hepatology 2016;63:1968\u20131976.","journal-title":"Hepatology"},{"key":"7134_CR31","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/hep.20066","volume":"39","author":"BA Runyon","year":"2004","unstructured":"Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004;39:841\u2013856.","journal-title":"Hepatology"},{"key":"7134_CR32","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1378\/chest.128.5.3233","volume":"128","author":"M Falguera","year":"2005","unstructured":"Falguera M, Pifarre R, Martin A et al. Etiology and outcome of community-acquired pneumonia in patients with diabetes mellitus. Chest 2005;128:3233\u20133239.","journal-title":"Chest"},{"key":"7134_CR33","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1378\/chest.99.5.1108","volume":"99","author":"BS Chertow","year":"1991","unstructured":"Chertow BS, Kadzielawa R, Burger AJ. Benign pleural effusions in long-standing diabetes mellitus. Chest 1991;99:1108\u20131111.","journal-title":"Chest"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-021-07134-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-021-07134-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-021-07134-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T19:24:45Z","timestamp":1656357885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-021-07134-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["7134"],"URL":"https:\/\/doi.org\/10.1007\/s10620-021-07134-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"22 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hugh Watson holds shares in Sanofi. No other disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}